Nilda Gonzalez-Roibon1, Jenny J Kim2, Sheila F Faraj1, Alcides Chaux3, Stephania M Bezerra1, Enrico Munari1, Carla Ellis1, Rajni Sharma1, Daniel Keizman4, Trinity J Bivalacqua4, Mark Schoenberg4, Mario Eisenberger4, Michael Carducci5, George J Netto6. 1. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD. 2. Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD. 3. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; Office of Scientific Research, Norte University, Asunción, Paraguay. 4. Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD. 5. Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD. 6. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: gnetto1@jhmi.edu.
Abstract
OBJECTIVE: To assess the insulin-like growth factor-1 receptor (IGF1R) expression in urothelial carcinoma (UC) and its prognostic role in relation to clinicopathologic parameters. METHODS: A total of 100 cases of invasive UC were evaluated using tissue microarrays. Membranous IGF1R staining was evaluated using immunohistochemistry. A scoring method analogous to that of HER2 expression in breast carcinoma was used, and the highest score was assigned in each tumor. IGF1R was considered overexpressed in cases with score≥1. RESULTS: We found IGF1R overexpression in 62% of invasive UC. IGF1R overexpression was associated with race (P=.04) and pT category (P=.03). Median follow-up was 29 months (range, 0.5-212). Progression rate was 60%, and overall mortality and cancer-specific mortality rates were 69% and 51%, respectively. In invasive UC, IGF1R overexpression was significantly associated with overall mortality and cancer-specific mortality (Mantel Cox P=.0002 and P=.006, respectively). IGF1R overexpression was associated with increased hazard ratios (HRs) for overall mortality (HR=2.63, P=.001) and cancer-specific mortality (HR=2.45, P=.01), independently and after adjusting for clinicopathologic features and treatment modalities. CONCLUSION: We found IGF1R overexpression in 62% of bladder UC. More importantly, IGF1R overexpression was a significant predictor of overall mortality and cancer-specific mortality, suggesting its potential role as a prognosticator in UC of bladder.
OBJECTIVE: To assess the insulin-like growth factor-1 receptor (IGF1R) expression in urothelial carcinoma (UC) and its prognostic role in relation to clinicopathologic parameters. METHODS: A total of 100 cases of invasive UC were evaluated using tissue microarrays. Membranous IGF1R staining was evaluated using immunohistochemistry. A scoring method analogous to that of HER2 expression in breast carcinoma was used, and the highest score was assigned in each tumor. IGF1R was considered overexpressed in cases with score≥1. RESULTS: We found IGF1R overexpression in 62% of invasive UC. IGF1R overexpression was associated with race (P=.04) and pT category (P=.03). Median follow-up was 29 months (range, 0.5-212). Progression rate was 60%, and overall mortality and cancer-specific mortality rates were 69% and 51%, respectively. In invasive UC, IGF1R overexpression was significantly associated with overall mortality and cancer-specific mortality (Mantel Cox P=.0002 and P=.006, respectively). IGF1R overexpression was associated with increased hazard ratios (HRs) for overall mortality (HR=2.63, P=.001) and cancer-specific mortality (HR=2.45, P=.01), independently and after adjusting for clinicopathologic features and treatment modalities. CONCLUSION: We found IGF1R overexpression in 62% of bladder UC. More importantly, IGF1R overexpression was a significant predictor of overall mortality and cancer-specific mortality, suggesting its potential role as a prognosticator in UC of bladder.
Authors: Mark W Ball; Stephania M Bezerra; Alcides Chaux; Sheila F Faraj; Nilda Gonzalez-Roibon; Enrico Munari; Rajni Sharma; Trinity J Bivalacqua; George J Netto; Arthur L Burnett Journal: Urology Date: 2016-02-18 Impact factor: 2.649
Authors: Sheila F Faraj; Nilda Gonzalez-Roibon; Enrico Munari; Rajni Sharma; Arthur L Burnett; Antonio L Cubilla; George J Netto; Alcides Chaux Journal: Virchows Arch Date: 2017-03-27 Impact factor: 4.064